Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 6 studies | 87% ± 13% | |
| cholangiocyte | 4 studies | 63% ± 27% | |
| endothelial cell | 4 studies | 48% ± 32% | |
| endothelial cell of sinusoid | 3 studies | 46% ± 17% | |
| hepatic stellate cell | 3 studies | 71% ± 20% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 4 studies | 66% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 932590.69 | 226 / 226 | 99% | 6375.83 | 400 / 406 |
| pancreas | 86% | 1143.95 | 282 / 328 | 40% | 52.02 | 72 / 178 |
| lung | 75% | 631.25 | 432 / 578 | 21% | 150.33 | 242 / 1155 |
| kidney | 73% | 1585.37 | 65 / 89 | 17% | 47.48 | 153 / 901 |
| stomach | 81% | 2138.72 | 290 / 359 | 4% | 5.56 | 12 / 286 |
| adrenal gland | 51% | 103.23 | 132 / 258 | 1% | 7.56 | 2 / 230 |
| spleen | 49% | 1445.71 | 118 / 241 | 0% | 0 | 0 / 0 |
| uterus | 41% | 56.02 | 70 / 170 | 2% | 1.75 | 11 / 459 |
| bladder | 38% | 58.52 | 8 / 21 | 3% | 9.25 | 14 / 504 |
| ovary | 38% | 55.61 | 68 / 180 | 0% | 0.05 | 1 / 430 |
| esophagus | 32% | 58.22 | 458 / 1445 | 4% | 9.84 | 8 / 183 |
| peripheral blood | 34% | 226.24 | 319 / 929 | 0% | 0 | 0 / 0 |
| intestine | 29% | 53.98 | 281 / 966 | 4% | 30.47 | 21 / 527 |
| prostate | 29% | 33.83 | 72 / 245 | 1% | 0.11 | 3 / 502 |
| thymus | 26% | 40.22 | 173 / 653 | 0% | 0.06 | 1 / 605 |
| breast | 24% | 91.16 | 110 / 459 | 1% | 10.27 | 12 / 1118 |
| blood vessel | 22% | 35.33 | 297 / 1335 | 0% | 0 | 0 / 0 |
| skin | 20% | 44.29 | 369 / 1809 | 1% | 0.54 | 5 / 472 |
| heart | 21% | 46.39 | 184 / 861 | 0% | 0 | 0 / 0 |
| adipose | 21% | 158.27 | 252 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 17% | 24.91 | 140 / 803 | 0% | 0 | 0 / 0 |
| brain | 14% | 16.52 | 363 / 2642 | 0% | 0.03 | 1 / 705 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_2000352 | Biological process | negative regulation of endothelial cell apoptotic process |
| GO_0072378 | Biological process | blood coagulation, fibrin clot formation |
| GO_0070527 | Biological process | platelet aggregation |
| GO_0045087 | Biological process | innate immune response |
| GO_0007160 | Biological process | cell-matrix adhesion |
| GO_0045907 | Biological process | positive regulation of vasoconstriction |
| GO_0072377 | Biological process | blood coagulation, common pathway |
| GO_0090277 | Biological process | positive regulation of peptide hormone secretion |
| GO_0042730 | Biological process | fibrinolysis |
| GO_0065003 | Biological process | protein-containing complex assembly |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0050714 | Biological process | positive regulation of protein secretion |
| GO_0051258 | Biological process | protein polymerization |
| GO_0034116 | Biological process | positive regulation of heterotypic cell-cell adhesion |
| GO_1900026 | Biological process | positive regulation of substrate adhesion-dependent cell spreading |
| GO_1902042 | Biological process | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors |
| GO_0043152 | Biological process | induction of bacterial agglutination |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_0051592 | Biological process | response to calcium ion |
| GO_0031639 | Biological process | plasminogen activation |
| GO_0045921 | Biological process | positive regulation of exocytosis |
| GO_0005615 | Cellular component | extracellular space |
| GO_0031091 | Cellular component | platelet alpha granule |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_1903561 | Cellular component | extracellular vesicle |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0072562 | Cellular component | blood microparticle |
| GO_0009986 | Cellular component | cell surface |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0031093 | Cellular component | platelet alpha granule lumen |
| GO_0005577 | Cellular component | fibrinogen complex |
| GO_0005201 | Molecular function | extracellular matrix structural constituent |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0005198 | Molecular function | structural molecule activity |
| GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0050839 | Molecular function | cell adhesion molecule binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FGA |
| Protein name | Fibrinogen alpha chain isoform 2 Fibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha chain] Fibrinogen alpha chain isoform 5 Fibrinogen alpha chain isoform 8 Fibrinogen alpha chain isoform 1 FGA protein |
| Synonyms | |
| Description | FUNCTION: Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways. . |
| Accessions | A0A0S2Z3E8 A0A0S2Z3E9 Q3KRA7 A0A0S2Z3P3 P02671 Q8WW76 ENST00000651975.2 [P02671-1] A0A0S2Z3M3 Q86Z09 ENST00000403106.8 [P02671-2] Q6NSD8 |
